Combination of cinacalcet, calcitriol, and lanthanum carbonate in treatment of secondary hyperparathyroidism in uremia under hemodialysis
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 9
Abstract
Objective To observe the efficacy of combined treatment with cinacalcet, calcitriol, and lanthanum carbonate in uremia patients undergoing hemodialysis (HD) with secondary hyperparathyroidism (SHPT). Methods From January 2020 to December 2022, 80 uremia patients under HD with SHPT treated at Huangshan City People's Hospital were selected. They were randomly divided into the control group (40 cases, treated with calcitriol) and the study group (40 cases, treated with a combination of cinacalcet, calcitriol, and lanthanum carbonate). The calcium-phosphorus product, intact parathyroid hormone (iPTH), parathyroid volume, and carotid intima-media thickness (IMT), as well as adverse reactions, were compared between the two groups. Results Compared with before treatment, both groups showed a decrease in calcium-phosphorus product and iPTH after 1, 3, and 6 months of treatment (P＜0.05). Moreover, compared with the control group, the study group had lower calcium-phosphorus product and iPTH after 1, 3, and 6 months of treatment (P＜0.05). Compared with before treatment, both groups showed a reduction in parathyroid volume after 1, 3, and 6 months of treatment (P＜0.05). The study group also showed a reduction in carotid IMT after 3 and 6 months of treatment (P＜0.05), while the control group showed a reduction in IMT after 6 months of treatment (P＜0.05). Furthermore, compared with the control group, the study group had lower parathyroid volume and IMT after 3 and 6 months of treatment (P＜0.05). The incidence of adverse reactions in the study group was 17.50%, which was not significantly different from the 15.00% in the control group (χ2=0.092, P=0.762). Conclusion For uremia patients under HD accompanied by SHPT, combined treatment of cinacalcet, calcitriol, and lanthanum carbonate can improve calcium and phosphorus metabolism, regulate iPTH, reduce parathyroid volume and the risk of carotid atherosclerosis, without increasing adverse reactions.
Authors and Affiliations
WANG Chengjun , WANG Hong, WAN Jiakui, SHAO Jue
Keywords
Related Articles
- EP ID EP745465
- DOI 10.13429/j.cnki.cjcr.2024.09.018
- Views 1
- Downloads 0
Correlation between microstream PETCO2 and PaCO2 in patients with general anesthesia after tracheal catheter removal
Objective To evaluate the correlation between microstream partial pressure of end-tidal carbon dioxide (PETCO2) and arterial partial pressure of carbon dioxide (PaCO2) in patients with general anesthesia after tracheal...
Expression and clinical significance of PD-1, PD-L1 and tumor infiltrating lymphocytes in neuroblastoma
<b>Objective</b> To investigate the expression of programmed cell death protein 1(PD-1), programmed cell death 1 ligand 1 (PD-L1) and tumor infiltrates lymphocytes (TIL) density in neuroblastoma and the relationship betw...
Research progress of left bundle branch block
Left bundle branch block (LBBB) is an important cause of heart failure. When LBBB occurs, the excitation sequence of the left ventricle changes, leading to the change of cardiac systolic pattern, resulting in cardiac ele...
Research progress on the mechanism of action of gut microbiota on hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has a high incidence rate among the malignant tumors reported in the world, and its incidence rate and mortality continue to rise. In recent years, researches have shown that the gut microb...
Study on the medication rule of Chinese medicine compound oral administration for the treatment of alopecia areata based on the national patent database
<b>Objective</b> To explore the medication rules of patented Chinese medicine compounds for oral administration in treating alopecia areata (AA), and provide reference for the treatment of AA with Chinese medicine and t...